Whether you are developing new immunotherapies for dogs or conducting veterinary research, our new dog antibody library was designed to give you the best reagents in less than 7 weeks. Endowed with huge diversity (1010), LibAb-SFDogTM bears the native repertoire of dozens of dogs from many different breeds. It is the first high-diversity naïve canine antibody library on the market.
Huge diversity from a wide variety of breeds
Outstanding clonal diversity of 1 x 1010 (scFv/Fab) obtained from samples of 46 individual dogs from 6 different breeds
Your antibody in 7 weeks
Get your native canine antibody in less than 7 weeks, ready for therapy or veterinary medicine research
Forgo the need for costly caninization
Antibody caninization processes are time-consuming, expensive, and risky. Save time and costs by opting for a therapy-ready and application-ready dog antibody discovery process
Receive at least 3 unique binders against your target antigen
Get full ownership over all generated native canine antibodies
Animal-free dog antibody discovery
Forgo the need for immunization thanks to the high diversity of our premium LiAb-SFDogTM library and the screening power of our phage display platform
Our new dog library (LiAb-SFDogTM) is the first naïve and high-diversity library on the market.
Antigen procurement or design and production
Library screening and biopanning
ELISA screening of single phage binders
Phage DNA extraction & antibody sequencing
Additional screening & analysis (optional)
Stable cell line
In the past decade, the use of immunotherapies in veterinary medicine has been gaining ground over conventional treatments. But one of the major challenges still hindering their widespread use is the limited availability of canine-specific reagents, vital to better understand dogs’ immune systems. Additionally, there are still significant gaps in knowledge concerning the genotype and phenotype of tumors in dogs and corresponding disease biomarkers. Although these limitations hamper the efforts of immunotherapy development for dogs, they also create an unprecedented opportunity for progress.
The lack of native antibodies was the main driving force behind the generation of our new premium dog antibody library – LiAb-SFDogTM. Being the first of its kind on the market, it offers an avenue for quickly generating antibodies for veterinary research and therapy. But what is known about the use of monoclonal antibodies to treat animals?
The proof that canine cancer was responsive to immunotherapy was provided in the 1960s with the first successful bone marrow transplant between littermates. Since then, the use of immunotherapy in dogs was shown to successfully tackle conditions such as sarcoma, lymphoma, mammary cancer, arthritis, dermatitis, and parvovirus infections, among others.
Antibodies are a hallmark of human medicine. In comparison, the development of new dog immunotherapeutics has lagged considerably. Currently, only a few therapies are commercially available in the USA and Canada:
In comparison to their human equivalents, these antibodies have shown limited effectiveness. One reason for this limitation may stem from the fact that these therapeutics have been developed by a process of caninization.
As the name indicates, this process is similar to antibody humanization. However, our limited knowledge regarding dog immunology has made caninization significantly more risky, expensive, and time-consuming than the humanization process. Moreover, disease targets may differ significantly between dogs and humans, making the process of target selection and antigen design suboptimal when it comes to the treatment of canine diseases.
Despite the current challenges, interesting breakthroughs were achieved in recent years in the development of efficient antibody treatments for dogs:
The generation of monoclonal antibodies targeting high-incidence diseases is expected to alleviate the burden imposed on the veterinary healthcare system. All available monoclonal antibody treatments for dogs are early generations (chimeric or caninized) with most of the biopharmaceuticals generated by caninization of xenogeneic antibodies (mouse, rat, etc.).
The promising results obtained with these antibodies suggest that the use of native dog antibodies would significantly boost the development of new, highly efficient, and cost-effective immunotherapies.
In parallel to the development of immunotherapies for dogs, many researchers are actively investigating the relevance and feasibility of using dogs as cancer animal models.
The dominant models of human disease at the preclinical stage are mouse models. Despite the wealth of knowledge generated by these models, they are prone to important limitations. For instance, due to their small size, it is challenging to study the importance of dose and dosage regimen in these models. Additionally, mice disease phenotypes often differ significantly from their human counterparts, making it harder to extrapolate results to the clinic.
In contrast, the use of dogs as disease models has been invaluable to increase our knowledge on pathogenesis and treatment efficacy. Dogs and humans share over 58% of diseases caused by mutations in the same genes. Moreover, a plethora of arguments makes they suited for preclinical studies including
Research shows that rodent models will continue to be essential for early proof-of-concept studies, particularly when it comes to their use as cancer models. However, these models have proven to be insufficient when estimating the ultimate effectiveness of new immunotherapies in humans (dosage and regimen-wise).
Dogs are large animals, sharing much with their human owners such as their immune response, disease markers, and exposure to the same or similar antigens. One particular area of research where the use of dogs as cancer models may bring great value is in the study of checkpoint molecule targeted immunotherapies. The use of checkpoint inhibitors in dogs both as monotherapies or combined therapeutic approaches (e.g., in combination with chemotherapy), would improve our knowledge regarding the effectiveness of these treatments, particularly against solid tumors where much research remains to be done.
Got a question or need a quote? Message us and we’ll get back to you 48 hours or less.